Owlet, Inc.

NYSE:OWLT

Medical - Devices

Healthcare
$3.67 +9.76%

+$0.46 today

Market cap
$107.24M
Beta
1.86
P/E (TTM)
-0.4
EPS (TTM)
-$12.67
52W Low $4.19High $16.94

Volume 0.64M

Average 0.24M

OWLT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Owlet, Inc.NYSE: OWLT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $3.96M rose 36.3% year over year, behind the +46.7% change in trailing-twelve-month research & development. Sequentially, it rose 8.8% from the prior quarter. Over 3 fiscal years it compounded at -20.4% a year.

Context

  • Research & development amounted to 13.3% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +36.3% toward the trailing-twelve-month pace of +46.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.96M+8.8% QoQ
Last fiscal yearDec 2025
$14.08M+43.6% YoY
LTMMar 2026
$15.13M+46.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+36.3%——
1 year+43.6%——
3-year CAGR-20.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
14.08M USD
Year-over-year change
+43.6%
4-year CAGR
-10.0%

Research & Development vs competitors

How OWLT compares with its peers on the latest reported figures

  • OWLT's LTM Mar 2026 research & development of $15.13M is the 7th highest of the 10 companies compared; the peer median is $23.84M.
  • Its year-over-year change of +46.7% is the 2nd highest of 10, against a peer median of -7.2%.
  • Research & development amounts to 14.1% of revenue for OWLT, versus a peer median of 58.2%.
OWLT Competitors Peer median
Research & Development for OWLT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$74.27M +76.4%+63.2%—
AVRAnteris Technologies Global Corp.LTM Mar 2026$70.12M +24.4%+57.8%3788.3%
CRDFCardiff Oncology, Inc.LTM Mar 2026$31.62M -19.6%+9.2%6022.3%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$26.42M +16.3%+12.0%22.7%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$23.84M -29.5%+13.5%—
MXCTMaxCyte, Inc.LTM Mar 2026$18.78M -12.5%+2.2%58.2%
OWLTOwlet, Inc.LTM Mar 2026$15.13M +46.7%-20.4%14.1%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$13.34M -7.2%+1.9%38.8%
LNSRLENSAR, Inc.LTM Mar 2026$5.47M +1.0%-21.9%9.5%
LUCDLucid Diagnostics Inc.LTM Mar 2026$5.46M -7.8%+691.2%106.3%
Peer median (excluding OWLT) $23.84M-7.2%+12.0%58.2%

Competitors are the stored peer set for OWLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.84M69.2M54.01M78.06M105.71M
Cost of Revenue40.78M45.89M31.42M38.75M52.18M
Gross Profit35.06M23.31M22.59M39.31M53.53M
Gross Margin46.2%33.7%41.8%50.4%50.6%
Research & Development21.43M27.9M10.35M9.8M14.08M
Selling, General & Admin69.42M80.04M40.87M49.73M47.72M
Operating Expenses90.85M107.93M51.22M59.53M61.79M
Depreciation & Amortization1.13M2.67M2.21M1.38M590K
EBITDA(42.71M)(75.53M)(27.49M)(9.47M)(35.64M)
EBITDA Margin-56.3%-109.1%-50.9%-12.1%-33.7%
Operating Income(55.79M)(84.62M)(28.63M)(20.22M)(8.26M)
Operating Margin-73.6%-122.3%-53.0%-25.9%-7.8%
Interest Income00000
Interest Expense27.83M1.1M3.19M1.63M3.42M
Other Income / Expenses(15.88M)5.31M(4.26M)7.74M(31.39M)
Income Before Tax(71.67M)(79.31M)(32.89M)(12.48M)(39.65M)
Pre-Tax Margin-94.5%-114.6%-60.9%-16.0%-37.5%
Income Tax Expense31K29K10K54K28K
Net Income(71.7M)(79.34M)(32.9M)(12.54M)(39.68M)
Net Margin-94.5%-114.6%-60.9%-16.1%-37.5%
EPS (Basic)(12.47)(9.97)(4.53)(0.83)(2.24)
EPS (Diluted)(12.47)(9.97)(4.53)(0.83)(2.24)
Weighted Avg Shares7.87M7.95M8.28M15.11M562.5M
Weighted Avg Shares (Diluted)7.87M7.95M8.28M15.11M562.5M

Owlet, Inc.

NYSE:OWLT

Intrinsic Alpha fair value

Locked

Current Price

$3.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.